Galectin Therapeutics, Inc. said it was issued a US patent for “Composition of Novel Carbohydrate Drug for Treatment of Human Diseases.”
The patent’s principal claims cover method of use for GR-MD-02 in patients with an autoimmune disease.
The patent coverage extends through 2032.
Galectin Therapeutics CEO Peter Traber said: “Our patent portfolio is an important asset for Galectin Therapeutics.
“Each patent and patent application is a strategic building block which reflects present and future business objectives and protects current core technology.
“This method of use patent protects the use of GR-MD-02 in the general category of autoimmune disease which covers multiple types of human diseases and strengthens our other patents.
“Galectin Therapeutics has multiple additional US and international patent applications pending.”